nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—Cytochrome P450 2D6 Inhibitors—Ritonavir—acquired immunodeficiency syndrome	0.167	0.232	CiPCiCtD
Everolimus—P-Glycoprotein Inhibitors—Lopinavir—acquired immunodeficiency syndrome	0.158	0.219	CiPCiCtD
Everolimus—Cytochrome P450 3A4 Inhibitors—Amprenavir—acquired immunodeficiency syndrome	0.124	0.172	CiPCiCtD
Everolimus—P-Glycoprotein Inhibitors—Ritonavir—acquired immunodeficiency syndrome	0.0959	0.133	CiPCiCtD
Everolimus—Cytochrome P450 3A4 Inhibitors—Ritonavir—acquired immunodeficiency syndrome	0.0882	0.122	CiPCiCtD
Everolimus—Cytochrome P450 3A4 Inhibitors—Efavirenz—acquired immunodeficiency syndrome	0.0882	0.122	CiPCiCtD
Everolimus—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0167	0.126	CbGbCtD
Everolimus—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0157	0.119	CbGbCtD
Everolimus—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0157	0.119	CbGbCtD
Everolimus—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0142	0.107	CbGbCtD
Everolimus—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0142	0.107	CbGbCtD
Everolimus—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0123	0.0925	CbGbCtD
Everolimus—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0119	0.0898	CbGbCtD
Everolimus—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0108	0.0812	CbGbCtD
Everolimus—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0108	0.0812	CbGbCtD
Everolimus—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0103	0.0779	CbGbCtD
Everolimus—MTOR—blood plasma—acquired immunodeficiency syndrome	0.0021	0.0888	CbGeAlD
Everolimus—FKBP1A—blood plasma—acquired immunodeficiency syndrome	0.00189	0.0799	CbGeAlD
Everolimus—MTOR—retina—acquired immunodeficiency syndrome	0.00115	0.0486	CbGeAlD
Everolimus—FKBP1A—retina—acquired immunodeficiency syndrome	0.00104	0.0437	CbGeAlD
Everolimus—MTOR—skin of body—acquired immunodeficiency syndrome	0.00101	0.0427	CbGeAlD
Everolimus—FKBP1A—skin of body—acquired immunodeficiency syndrome	0.000909	0.0384	CbGeAlD
Everolimus—MTOR—lymphoid tissue—acquired immunodeficiency syndrome	0.000818	0.0346	CbGeAlD
Everolimus—MTOR—digestive system—acquired immunodeficiency syndrome	0.000808	0.0341	CbGeAlD
Everolimus—MTOR—blood—acquired immunodeficiency syndrome	0.00077	0.0325	CbGeAlD
Everolimus—MTOR—bone marrow—acquired immunodeficiency syndrome	0.000745	0.0315	CbGeAlD
Everolimus—MTOR—spinal cord—acquired immunodeficiency syndrome	0.000742	0.0313	CbGeAlD
Everolimus—FKBP1A—lymphoid tissue—acquired immunodeficiency syndrome	0.000736	0.0311	CbGeAlD
Everolimus—FKBP1A—digestive system—acquired immunodeficiency syndrome	0.000727	0.0307	CbGeAlD
Everolimus—MTOR—vagina—acquired immunodeficiency syndrome	0.000714	0.0302	CbGeAlD
Everolimus—FKBP1A—blood—acquired immunodeficiency syndrome	0.000692	0.0293	CbGeAlD
Everolimus—MTOR—lung—acquired immunodeficiency syndrome	0.000675	0.0285	CbGeAlD
Everolimus—FKBP1A—bone marrow—acquired immunodeficiency syndrome	0.00067	0.0283	CbGeAlD
Everolimus—FKBP1A—spinal cord—acquired immunodeficiency syndrome	0.000667	0.0282	CbGeAlD
Everolimus—FKBP1A—vagina—acquired immunodeficiency syndrome	0.000642	0.0271	CbGeAlD
Everolimus—MTOR—nervous system—acquired immunodeficiency syndrome	0.000625	0.0264	CbGeAlD
Everolimus—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000618	0.0261	CbGeAlD
Everolimus—FKBP1A—lung—acquired immunodeficiency syndrome	0.000607	0.0257	CbGeAlD
Everolimus—MTOR—central nervous system—acquired immunodeficiency syndrome	0.000602	0.0254	CbGeAlD
Everolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—CCNT1—acquired immunodeficiency syndrome	0.000563	0.0664	CbGpPWpGaD
Everolimus—FKBP1A—nervous system—acquired immunodeficiency syndrome	0.000562	0.0238	CbGeAlD
Everolimus—FKBP1A—central nervous system—acquired immunodeficiency syndrome	0.000541	0.0229	CbGeAlD
Everolimus—MTOR—brain—acquired immunodeficiency syndrome	0.000478	0.0202	CbGeAlD
Everolimus—MTOR—lymph node—acquired immunodeficiency syndrome	0.000462	0.0195	CbGeAlD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—acquired immunodeficiency syndrome	0.000454	0.0535	CbGpPWpGaD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CSF2—acquired immunodeficiency syndrome	0.000449	0.0529	CbGpPWpGaD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL4—acquired immunodeficiency syndrome	0.000442	0.052	CbGpPWpGaD
Everolimus—FKBP1A—brain—acquired immunodeficiency syndrome	0.00043	0.0182	CbGeAlD
Everolimus—FKBP1A—lymph node—acquired immunodeficiency syndrome	0.000415	0.0175	CbGeAlD
Everolimus—MTOR—IL12-mediated signaling events—CCL4—acquired immunodeficiency syndrome	0.000324	0.0382	CbGpPWpGaD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IFNG—acquired immunodeficiency syndrome	0.000267	0.0314	CbGpPWpGaD
Everolimus—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000238	0.01	CbGeAlD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2—acquired immunodeficiency syndrome	0.000237	0.0279	CbGpPWpGaD
Everolimus—CYP3A4—blood—acquired immunodeficiency syndrome	0.000226	0.00956	CbGeAlD
Everolimus—MTOR—IL12-mediated signaling events—CCL3—acquired immunodeficiency syndrome	0.000221	0.0261	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	0.000207	0.0244	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—APOBEC3G—acquired immunodeficiency syndrome	0.000201	0.0237	CbGpPWpGaD
Everolimus—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000184	0.00776	CbGeAlD
Everolimus—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000177	0.00747	CbGeAlD
Everolimus—Tacrolimus—ALB—acquired immunodeficiency syndrome	0.000163	1	CrCbGaD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—IFNG—acquired immunodeficiency syndrome	0.000162	0.0191	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—CXCL12—acquired immunodeficiency syndrome	0.000144	0.0169	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—CXCR4—acquired immunodeficiency syndrome	0.000144	0.0169	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	0.000144	0.0169	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—CCL3—acquired immunodeficiency syndrome	0.000142	0.0167	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—CD8A—acquired immunodeficiency syndrome	0.000141	0.0166	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.000139	0.0164	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.000139	0.0164	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000139	0.0163	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000135	0.0159	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—CCR5—acquired immunodeficiency syndrome	0.000129	0.0152	CbGpPWpGaD
Everolimus—MTOR—Type II diabetes mellitus—TNF—acquired immunodeficiency syndrome	0.000121	0.0143	CbGpPWpGaD
Everolimus—MTOR—IL2 signaling events mediated by PI3K—IL2—acquired immunodeficiency syndrome	0.00011	0.0129	CbGpPWpGaD
Everolimus—MTOR—IFN-gamma pathway—IFNG—acquired immunodeficiency syndrome	0.00011	0.0129	CbGpPWpGaD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—acquired immunodeficiency syndrome	0.000105	0.0124	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—CXCL12—acquired immunodeficiency syndrome	8.95e-05	0.0105	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	8.69e-05	0.0102	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IFNG—acquired immunodeficiency syndrome	8.39e-05	0.00988	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—CD4—acquired immunodeficiency syndrome	8.1e-05	0.00954	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	7.72e-05	0.00909	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—IFNG—acquired immunodeficiency syndrome	7.59e-05	0.00894	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IL2—acquired immunodeficiency syndrome	7.46e-05	0.00878	CbGpPWpGaD
Everolimus—MTOR—Costimulation by the CD28 family—CD4—acquired immunodeficiency syndrome	7.33e-05	0.00863	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—CD79A—acquired immunodeficiency syndrome	6.82e-05	0.00803	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—IL2—acquired immunodeficiency syndrome	6.75e-05	0.00794	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APOBEC3G—acquired immunodeficiency syndrome	6.59e-05	0.00776	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.48e-05	0.00763	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—CD4—acquired immunodeficiency syndrome	6.19e-05	0.00729	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—TNF—acquired immunodeficiency syndrome	5.82e-05	0.00686	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HLA-B—acquired immunodeficiency syndrome	5.71e-05	0.00673	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	5.62e-05	0.00662	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CCNT1—acquired immunodeficiency syndrome	5.6e-05	0.0066	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—acquired immunodeficiency syndrome	5.36e-05	0.00632	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—IL6—acquired immunodeficiency syndrome	5.33e-05	0.00628	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	5.08e-05	0.00599	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	4.54e-05	0.00534	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MBL2—acquired immunodeficiency syndrome	4.18e-05	0.00492	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	4.15e-05	0.00489	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.92e-05	0.00462	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.92e-05	0.00462	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	3.82e-05	0.0045	CbGpPWpGaD
Everolimus—MTOR—Disease—APOBEC3G—acquired immunodeficiency syndrome	3.71e-05	0.00437	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.64e-05	0.00429	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.55e-05	0.00418	CbGpPWpGaD
Everolimus—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	3.53e-05	0.000311	CcSEcCtD
Everolimus—Pruritus—Stavudine—acquired immunodeficiency syndrome	3.52e-05	0.000311	CcSEcCtD
Everolimus—Asthenia—Abacavir—acquired immunodeficiency syndrome	3.52e-05	0.00031	CcSEcCtD
Everolimus—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	3.52e-05	0.00031	CcSEcCtD
Everolimus—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	3.51e-05	0.00031	CcSEcCtD
Everolimus—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	3.51e-05	0.000309	CcSEcCtD
Everolimus—Chest pain—Ritonavir—acquired immunodeficiency syndrome	3.51e-05	0.000309	CcSEcCtD
Everolimus—Myalgia—Ritonavir—acquired immunodeficiency syndrome	3.51e-05	0.000309	CcSEcCtD
Everolimus—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	3.5e-05	0.000308	CcSEcCtD
Everolimus—Anaemia—Lamivudine—acquired immunodeficiency syndrome	3.5e-05	0.000308	CcSEcCtD
Everolimus—Anxiety—Ritonavir—acquired immunodeficiency syndrome	3.5e-05	0.000308	CcSEcCtD
Everolimus—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	3.49e-05	0.000307	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	3.49e-05	0.000307	CcSEcCtD
Everolimus—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	3.47e-05	0.000306	CcSEcCtD
Everolimus—Pruritus—Abacavir—acquired immunodeficiency syndrome	3.47e-05	0.000306	CcSEcCtD
Everolimus—Fatigue—Indinavir—acquired immunodeficiency syndrome	3.47e-05	0.000306	CcSEcCtD
Everolimus—Anorexia—Delavirdine—acquired immunodeficiency syndrome	3.47e-05	0.000306	CcSEcCtD
Everolimus—Discomfort—Ritonavir—acquired immunodeficiency syndrome	3.47e-05	0.000306	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	3.46e-05	0.000305	CcSEcCtD
Everolimus—Cough—Saquinavir—acquired immunodeficiency syndrome	3.46e-05	0.000305	CcSEcCtD
Everolimus—Angioedema—Lamivudine—acquired immunodeficiency syndrome	3.46e-05	0.000305	CcSEcCtD
Everolimus—Constipation—Indinavir—acquired immunodeficiency syndrome	3.44e-05	0.000303	CcSEcCtD
Everolimus—Pain—Indinavir—acquired immunodeficiency syndrome	3.44e-05	0.000303	CcSEcCtD
Everolimus—Insomnia—Efavirenz—acquired immunodeficiency syndrome	3.44e-05	0.000303	CcSEcCtD
Everolimus—Convulsion—Saquinavir—acquired immunodeficiency syndrome	3.44e-05	0.000303	CcSEcCtD
Everolimus—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	3.43e-05	0.000303	CcSEcCtD
Everolimus—Hypertension—Saquinavir—acquired immunodeficiency syndrome	3.43e-05	0.000302	CcSEcCtD
Everolimus—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	3.42e-05	0.000302	CcSEcCtD
Everolimus—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	3.42e-05	0.000302	CcSEcCtD
Everolimus—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	3.42e-05	0.000301	CcSEcCtD
Everolimus—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	3.41e-05	0.000301	CcSEcCtD
Everolimus—Malaise—Lamivudine—acquired immunodeficiency syndrome	3.41e-05	0.000301	CcSEcCtD
Everolimus—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	3.41e-05	0.0003	CcSEcCtD
Everolimus—Nausea—Didanosine—acquired immunodeficiency syndrome	3.41e-05	0.0003	CcSEcCtD
Everolimus—Hypotension—Delavirdine—acquired immunodeficiency syndrome	3.4e-05	0.0003	CcSEcCtD
Everolimus—Syncope—Lamivudine—acquired immunodeficiency syndrome	3.39e-05	0.000299	CcSEcCtD
Everolimus—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	3.39e-05	0.000299	CcSEcCtD
Everolimus—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	3.39e-05	0.000299	CcSEcCtD
Everolimus—Somnolence—Efavirenz—acquired immunodeficiency syndrome	3.38e-05	0.000298	CcSEcCtD
Everolimus—Myalgia—Saquinavir—acquired immunodeficiency syndrome	3.38e-05	0.000298	CcSEcCtD
Everolimus—Chest pain—Saquinavir—acquired immunodeficiency syndrome	3.38e-05	0.000298	CcSEcCtD
Everolimus—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	3.38e-05	0.000298	CcSEcCtD
Everolimus—Anxiety—Saquinavir—acquired immunodeficiency syndrome	3.37e-05	0.000297	CcSEcCtD
Everolimus—Oedema—Ritonavir—acquired immunodeficiency syndrome	3.36e-05	0.000297	CcSEcCtD
Everolimus—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	3.36e-05	0.000296	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	3.35e-05	0.000296	CcSEcCtD
Everolimus—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	3.35e-05	0.000295	CcSEcCtD
Everolimus—Discomfort—Saquinavir—acquired immunodeficiency syndrome	3.34e-05	0.000294	CcSEcCtD
Everolimus—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	3.33e-05	0.000293	CcSEcCtD
Everolimus—MTOR—IRS-mediated signalling—IL6—acquired immunodeficiency syndrome	3.32e-05	0.00391	CbGpPWpGaD
Everolimus—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	3.32e-05	0.000292	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	3.31e-05	0.000292	CcSEcCtD
Everolimus—Shock—Ritonavir—acquired immunodeficiency syndrome	3.31e-05	0.000292	CcSEcCtD
Everolimus—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	3.31e-05	0.000291	CcSEcCtD
Everolimus—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	3.3e-05	0.000291	CcSEcCtD
Everolimus—Cough—Lamivudine—acquired immunodeficiency syndrome	3.3e-05	0.000291	CcSEcCtD
Everolimus—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	3.3e-05	0.000291	CcSEcCtD
Everolimus—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	3.3e-05	0.000291	CcSEcCtD
Everolimus—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	3.29e-05	0.00029	CcSEcCtD
Everolimus—Dizziness—Stavudine—acquired immunodeficiency syndrome	3.29e-05	0.00029	CcSEcCtD
Everolimus—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	3.29e-05	0.00029	CcSEcCtD
Everolimus—Insomnia—Delavirdine—acquired immunodeficiency syndrome	3.29e-05	0.00029	CcSEcCtD
Everolimus—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	3.28e-05	0.000289	CcSEcCtD
Everolimus—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	3.28e-05	0.000289	CcSEcCtD
Everolimus—Convulsion—Lamivudine—acquired immunodeficiency syndrome	3.28e-05	0.000289	CcSEcCtD
Everolimus—Vomiting—Nevirapine—acquired immunodeficiency syndrome	3.28e-05	0.000289	CcSEcCtD
Everolimus—Fatigue—Efavirenz—acquired immunodeficiency syndrome	3.28e-05	0.000289	CcSEcCtD
Everolimus—MTOR—Innate Immune System—CCR2—acquired immunodeficiency syndrome	3.28e-05	0.00386	CbGpPWpGaD
Everolimus—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	3.27e-05	0.000288	CcSEcCtD
Everolimus—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	3.27e-05	0.000288	CcSEcCtD
Everolimus—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	3.25e-05	0.000287	CcSEcCtD
Everolimus—Constipation—Efavirenz—acquired immunodeficiency syndrome	3.25e-05	0.000287	CcSEcCtD
Everolimus—Pain—Efavirenz—acquired immunodeficiency syndrome	3.25e-05	0.000287	CcSEcCtD
Everolimus—Rash—Nevirapine—acquired immunodeficiency syndrome	3.25e-05	0.000287	CcSEcCtD
Everolimus—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	3.25e-05	0.000286	CcSEcCtD
Everolimus—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	3.24e-05	0.000286	CcSEcCtD
Everolimus—Dizziness—Abacavir—acquired immunodeficiency syndrome	3.24e-05	0.000286	CcSEcCtD
Everolimus—Oedema—Saquinavir—acquired immunodeficiency syndrome	3.24e-05	0.000285	CcSEcCtD
Everolimus—Somnolence—Delavirdine—acquired immunodeficiency syndrome	3.23e-05	0.000285	CcSEcCtD
Everolimus—Headache—Nevirapine—acquired immunodeficiency syndrome	3.23e-05	0.000285	CcSEcCtD
Everolimus—MTOR—IRS-related events—IL6—acquired immunodeficiency syndrome	3.23e-05	0.0038	CbGpPWpGaD
Everolimus—Myalgia—Lamivudine—acquired immunodeficiency syndrome	3.22e-05	0.000284	CcSEcCtD
Everolimus—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	3.22e-05	0.000284	CcSEcCtD
Everolimus—Chest pain—Lamivudine—acquired immunodeficiency syndrome	3.22e-05	0.000284	CcSEcCtD
Everolimus—Infection—Saquinavir—acquired immunodeficiency syndrome	3.22e-05	0.000284	CcSEcCtD
Everolimus—Anxiety—Lamivudine—acquired immunodeficiency syndrome	3.21e-05	0.000283	CcSEcCtD
Everolimus—Anorexia—Ritonavir—acquired immunodeficiency syndrome	3.21e-05	0.000283	CcSEcCtD
Everolimus—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	3.2e-05	0.000282	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	3.2e-05	0.000282	CcSEcCtD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	3.2e-05	0.00377	CbGpPWpGaD
Everolimus—Shock—Saquinavir—acquired immunodeficiency syndrome	3.19e-05	0.000281	CcSEcCtD
Everolimus—Discomfort—Lamivudine—acquired immunodeficiency syndrome	3.18e-05	0.000281	CcSEcCtD
Everolimus—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	3.18e-05	0.00028	CcSEcCtD
Everolimus—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	3.18e-05	0.00028	CcSEcCtD
Everolimus—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	3.18e-05	0.00028	CcSEcCtD
Everolimus—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	3.18e-05	0.00028	CcSEcCtD
Everolimus—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	3.17e-05	0.000279	CcSEcCtD
Everolimus—Vomiting—Stavudine—acquired immunodeficiency syndrome	3.17e-05	0.000279	CcSEcCtD
Everolimus—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	3.16e-05	0.000279	CcSEcCtD
Everolimus—MTOR—Disease—CCNT1—acquired immunodeficiency syndrome	3.15e-05	0.00371	CbGpPWpGaD
Everolimus—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	3.15e-05	0.000278	CcSEcCtD
Everolimus—Rash—Nelfinavir—acquired immunodeficiency syndrome	3.15e-05	0.000278	CcSEcCtD
Everolimus—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	3.15e-05	0.000277	CcSEcCtD
Everolimus—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	3.15e-05	0.000277	CcSEcCtD
Everolimus—Hypotension—Ritonavir—acquired immunodeficiency syndrome	3.14e-05	0.000277	CcSEcCtD
Everolimus—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	3.14e-05	0.000277	CcSEcCtD
Everolimus—Rash—Stavudine—acquired immunodeficiency syndrome	3.14e-05	0.000277	CcSEcCtD
Everolimus—Fatigue—Delavirdine—acquired immunodeficiency syndrome	3.14e-05	0.000277	CcSEcCtD
Everolimus—Dermatitis—Stavudine—acquired immunodeficiency syndrome	3.14e-05	0.000276	CcSEcCtD
Everolimus—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	3.13e-05	0.000276	CcSEcCtD
Everolimus—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	3.13e-05	0.000276	CcSEcCtD
Everolimus—Headache—Nelfinavir—acquired immunodeficiency syndrome	3.13e-05	0.000276	CcSEcCtD
Everolimus—Headache—Stavudine—acquired immunodeficiency syndrome	3.12e-05	0.000275	CcSEcCtD
Everolimus—Vomiting—Abacavir—acquired immunodeficiency syndrome	3.12e-05	0.000275	CcSEcCtD
Everolimus—MTOR—Insulin receptor signalling cascade—IL6—acquired immunodeficiency syndrome	3.11e-05	0.00367	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—IL6—acquired immunodeficiency syndrome	3.11e-05	0.00367	CbGpPWpGaD
Everolimus—Constipation—Delavirdine—acquired immunodeficiency syndrome	3.11e-05	0.000274	CcSEcCtD
Everolimus—Pain—Delavirdine—acquired immunodeficiency syndrome	3.11e-05	0.000274	CcSEcCtD
Everolimus—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	3.11e-05	0.000274	CcSEcCtD
Everolimus—Asthenia—Zidovudine—acquired immunodeficiency syndrome	3.1e-05	0.000274	CcSEcCtD
Everolimus—Rash—Abacavir—acquired immunodeficiency syndrome	3.09e-05	0.000273	CcSEcCtD
Everolimus—Dermatitis—Abacavir—acquired immunodeficiency syndrome	3.09e-05	0.000272	CcSEcCtD
Everolimus—Oedema—Lamivudine—acquired immunodeficiency syndrome	3.09e-05	0.000272	CcSEcCtD
Everolimus—Anorexia—Saquinavir—acquired immunodeficiency syndrome	3.09e-05	0.000272	CcSEcCtD
Everolimus—Headache—Abacavir—acquired immunodeficiency syndrome	3.07e-05	0.000271	CcSEcCtD
Everolimus—Infection—Lamivudine—acquired immunodeficiency syndrome	3.07e-05	0.000271	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	3.07e-05	0.00027	CcSEcCtD
Everolimus—Nausea—Nevirapine—acquired immunodeficiency syndrome	3.06e-05	0.00027	CcSEcCtD
Everolimus—Pruritus—Zidovudine—acquired immunodeficiency syndrome	3.06e-05	0.00027	CcSEcCtD
Everolimus—Insomnia—Ritonavir—acquired immunodeficiency syndrome	3.04e-05	0.000268	CcSEcCtD
Everolimus—Shock—Lamivudine—acquired immunodeficiency syndrome	3.04e-05	0.000268	CcSEcCtD
Everolimus—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	3.03e-05	0.000267	CcSEcCtD
Everolimus—Hypotension—Saquinavir—acquired immunodeficiency syndrome	3.03e-05	0.000267	CcSEcCtD
Everolimus—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	3.02e-05	0.000267	CcSEcCtD
Everolimus—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	3.02e-05	0.000266	CcSEcCtD
Everolimus—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	3.01e-05	0.000265	CcSEcCtD
Everolimus—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	3.01e-05	0.000265	CcSEcCtD
Everolimus—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	3e-05	0.000265	CcSEcCtD
Everolimus—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	3e-05	0.000264	CcSEcCtD
Everolimus—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	3e-05	0.000264	CcSEcCtD
Everolimus—Somnolence—Ritonavir—acquired immunodeficiency syndrome	2.99e-05	0.000264	CcSEcCtD
Everolimus—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	2.99e-05	0.000263	CcSEcCtD
Everolimus—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	2.98e-05	0.000262	CcSEcCtD
Everolimus—Nausea—Nelfinavir—acquired immunodeficiency syndrome	2.97e-05	0.000261	CcSEcCtD
Everolimus—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	2.97e-05	0.000261	CcSEcCtD
Everolimus—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	2.96e-05	0.000261	CcSEcCtD
Everolimus—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	2.96e-05	0.000261	CcSEcCtD
Everolimus—MTOR—Immune System—ACTG1—acquired immunodeficiency syndrome	2.96e-05	0.00349	CbGpPWpGaD
Everolimus—Nausea—Stavudine—acquired immunodeficiency syndrome	2.96e-05	0.000261	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	2.95e-05	0.00026	CcSEcCtD
Everolimus—MTOR—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	2.95e-05	0.00347	CbGpPWpGaD
Everolimus—Anorexia—Lamivudine—acquired immunodeficiency syndrome	2.94e-05	0.00026	CcSEcCtD
Everolimus—FKBP1A—Disease—CXCR4—acquired immunodeficiency syndrome	2.94e-05	0.00347	CbGpPWpGaD
Everolimus—Insomnia—Saquinavir—acquired immunodeficiency syndrome	2.93e-05	0.000258	CcSEcCtD
Everolimus—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	2.92e-05	0.000258	CcSEcCtD
Everolimus—Nausea—Abacavir—acquired immunodeficiency syndrome	2.91e-05	0.000257	CcSEcCtD
Everolimus—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	2.91e-05	0.000256	CcSEcCtD
Everolimus—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	2.9e-05	0.000256	CcSEcCtD
Everolimus—Fatigue—Ritonavir—acquired immunodeficiency syndrome	2.9e-05	0.000256	CcSEcCtD
Everolimus—Asthenia—Indinavir—acquired immunodeficiency syndrome	2.89e-05	0.000255	CcSEcCtD
Everolimus—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	2.89e-05	0.000254	CcSEcCtD
Everolimus—Hypotension—Lamivudine—acquired immunodeficiency syndrome	2.89e-05	0.000254	CcSEcCtD
Everolimus—Somnolence—Saquinavir—acquired immunodeficiency syndrome	2.88e-05	0.000254	CcSEcCtD
Everolimus—Pain—Ritonavir—acquired immunodeficiency syndrome	2.88e-05	0.000254	CcSEcCtD
Everolimus—Constipation—Ritonavir—acquired immunodeficiency syndrome	2.88e-05	0.000254	CcSEcCtD
Everolimus—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	2.88e-05	0.000254	CcSEcCtD
Everolimus—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	2.88e-05	0.000254	CcSEcCtD
Everolimus—Dizziness—Zidovudine—acquired immunodeficiency syndrome	2.86e-05	0.000252	CcSEcCtD
Everolimus—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	2.85e-05	0.000251	CcSEcCtD
Everolimus—Pruritus—Indinavir—acquired immunodeficiency syndrome	2.85e-05	0.000251	CcSEcCtD
Everolimus—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	2.81e-05	0.000248	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	2.81e-05	0.000248	CcSEcCtD
Everolimus—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	2.8e-05	0.000247	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL6—acquired immunodeficiency syndrome	2.8e-05	0.0033	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	2.8e-05	0.000246	CcSEcCtD
Everolimus—Insomnia—Lamivudine—acquired immunodeficiency syndrome	2.79e-05	0.000246	CcSEcCtD
Everolimus—Fatigue—Saquinavir—acquired immunodeficiency syndrome	2.79e-05	0.000246	CcSEcCtD
Everolimus—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	2.77e-05	0.000245	CcSEcCtD
Everolimus—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	2.77e-05	0.000244	CcSEcCtD
Everolimus—Pain—Saquinavir—acquired immunodeficiency syndrome	2.77e-05	0.000244	CcSEcCtD
Everolimus—Constipation—Saquinavir—acquired immunodeficiency syndrome	2.77e-05	0.000244	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—acquired immunodeficiency syndrome	2.76e-05	0.00325	CbGpPWpGaD
Everolimus—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	2.75e-05	0.000243	CcSEcCtD
Everolimus—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	2.75e-05	0.000243	CcSEcCtD
Everolimus—Vomiting—Zidovudine—acquired immunodeficiency syndrome	2.75e-05	0.000243	CcSEcCtD
Everolimus—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	2.75e-05	0.000243	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	2.75e-05	0.00324	CbGpPWpGaD
Everolimus—Somnolence—Lamivudine—acquired immunodeficiency syndrome	2.75e-05	0.000242	CcSEcCtD
Everolimus—Rash—Zidovudine—acquired immunodeficiency syndrome	2.73e-05	0.000241	CcSEcCtD
Everolimus—Asthenia—Efavirenz—acquired immunodeficiency syndrome	2.73e-05	0.00024	CcSEcCtD
Everolimus—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	2.73e-05	0.00024	CcSEcCtD
Everolimus—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	2.72e-05	0.00024	CcSEcCtD
Everolimus—Headache—Zidovudine—acquired immunodeficiency syndrome	2.71e-05	0.000239	CcSEcCtD
Everolimus—Pruritus—Efavirenz—acquired immunodeficiency syndrome	2.69e-05	0.000237	CcSEcCtD
Everolimus—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	2.69e-05	0.000237	CcSEcCtD
Everolimus—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	2.68e-05	0.000236	CcSEcCtD
Everolimus—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	2.67e-05	0.000235	CcSEcCtD
Everolimus—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	2.67e-05	0.000235	CcSEcCtD
Everolimus—Fatigue—Lamivudine—acquired immunodeficiency syndrome	2.66e-05	0.000235	CcSEcCtD
Everolimus—Dizziness—Indinavir—acquired immunodeficiency syndrome	2.66e-05	0.000235	CcSEcCtD
Everolimus—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	2.66e-05	0.000234	CcSEcCtD
Everolimus—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	2.66e-05	0.000234	CcSEcCtD
Everolimus—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	2.65e-05	0.000233	CcSEcCtD
Everolimus—Pain—Lamivudine—acquired immunodeficiency syndrome	2.64e-05	0.000233	CcSEcCtD
Everolimus—Constipation—Lamivudine—acquired immunodeficiency syndrome	2.64e-05	0.000233	CcSEcCtD
Everolimus—Asthenia—Delavirdine—acquired immunodeficiency syndrome	2.61e-05	0.00023	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	2.6e-05	0.00307	CbGpPWpGaD
Everolimus—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	2.6e-05	0.000229	CcSEcCtD
Everolimus—MTOR—Signaling by Insulin receptor—IL6—acquired immunodeficiency syndrome	2.59e-05	0.00305	CbGpPWpGaD
Everolimus—Pruritus—Delavirdine—acquired immunodeficiency syndrome	2.57e-05	0.000227	CcSEcCtD
Everolimus—Nausea—Zidovudine—acquired immunodeficiency syndrome	2.57e-05	0.000227	CcSEcCtD
Everolimus—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	2.56e-05	0.000226	CcSEcCtD
Everolimus—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	2.56e-05	0.000226	CcSEcCtD
Everolimus—Vomiting—Indinavir—acquired immunodeficiency syndrome	2.56e-05	0.000226	CcSEcCtD
Everolimus—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	2.55e-05	0.000224	CcSEcCtD
Everolimus—Rash—Indinavir—acquired immunodeficiency syndrome	2.54e-05	0.000224	CcSEcCtD
Everolimus—Dermatitis—Indinavir—acquired immunodeficiency syndrome	2.54e-05	0.000223	CcSEcCtD
Everolimus—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	2.53e-05	0.000223	CcSEcCtD
Everolimus—Headache—Indinavir—acquired immunodeficiency syndrome	2.52e-05	0.000222	CcSEcCtD
Everolimus—Dizziness—Efavirenz—acquired immunodeficiency syndrome	2.51e-05	0.000222	CcSEcCtD
Everolimus—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	2.49e-05	0.000219	CcSEcCtD
Everolimus—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	2.48e-05	0.000219	CcSEcCtD
Everolimus—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	2.44e-05	0.000215	CcSEcCtD
Everolimus—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	2.44e-05	0.000215	CcSEcCtD
Everolimus—MTOR—Immune System—MBL2—acquired immunodeficiency syndrome	2.43e-05	0.00286	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.42e-05	0.00286	CbGpPWpGaD
Everolimus—Vomiting—Efavirenz—acquired immunodeficiency syndrome	2.42e-05	0.000213	CcSEcCtD
Everolimus—Asthenia—Ritonavir—acquired immunodeficiency syndrome	2.41e-05	0.000213	CcSEcCtD
Everolimus—Dizziness—Delavirdine—acquired immunodeficiency syndrome	2.41e-05	0.000212	CcSEcCtD
Everolimus—Rash—Efavirenz—acquired immunodeficiency syndrome	2.4e-05	0.000211	CcSEcCtD
Everolimus—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	2.4e-05	0.000211	CcSEcCtD
Everolimus—Nausea—Indinavir—acquired immunodeficiency syndrome	2.39e-05	0.000211	CcSEcCtD
Everolimus—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	2.39e-05	0.00021	CcSEcCtD
Everolimus—Headache—Efavirenz—acquired immunodeficiency syndrome	2.38e-05	0.00021	CcSEcCtD
Everolimus—Pruritus—Ritonavir—acquired immunodeficiency syndrome	2.38e-05	0.00021	CcSEcCtD
Everolimus—Asthenia—Saquinavir—acquired immunodeficiency syndrome	2.32e-05	0.000205	CcSEcCtD
Everolimus—Vomiting—Delavirdine—acquired immunodeficiency syndrome	2.31e-05	0.000204	CcSEcCtD
Everolimus—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	2.3e-05	0.000203	CcSEcCtD
Everolimus—Rash—Delavirdine—acquired immunodeficiency syndrome	2.29e-05	0.000202	CcSEcCtD
Everolimus—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	2.29e-05	0.000202	CcSEcCtD
Everolimus—Pruritus—Saquinavir—acquired immunodeficiency syndrome	2.29e-05	0.000202	CcSEcCtD
Everolimus—Headache—Delavirdine—acquired immunodeficiency syndrome	2.28e-05	0.000201	CcSEcCtD
Everolimus—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	2.28e-05	0.000201	CcSEcCtD
Everolimus—Nausea—Efavirenz—acquired immunodeficiency syndrome	2.26e-05	0.000199	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	2.24e-05	0.00264	CbGpPWpGaD
Everolimus—Dizziness—Ritonavir—acquired immunodeficiency syndrome	2.22e-05	0.000196	CcSEcCtD
Everolimus—MTOR—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	2.22e-05	0.00261	CbGpPWpGaD
Everolimus—Asthenia—Lamivudine—acquired immunodeficiency syndrome	2.22e-05	0.000195	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	2.22e-05	0.00261	CbGpPWpGaD
Everolimus—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	2.22e-05	0.000195	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	2.21e-05	0.00261	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.21e-05	0.0026	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.21e-05	0.0026	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.19e-05	0.00258	CbGpPWpGaD
Everolimus—Pruritus—Lamivudine—acquired immunodeficiency syndrome	2.19e-05	0.000193	CcSEcCtD
Everolimus—Nausea—Delavirdine—acquired immunodeficiency syndrome	2.16e-05	0.000191	CcSEcCtD
Everolimus—Dizziness—Saquinavir—acquired immunodeficiency syndrome	2.14e-05	0.000189	CcSEcCtD
Everolimus—Vomiting—Ritonavir—acquired immunodeficiency syndrome	2.14e-05	0.000189	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	2.13e-05	0.00251	CbGpPWpGaD
Everolimus—Rash—Ritonavir—acquired immunodeficiency syndrome	2.12e-05	0.000187	CcSEcCtD
Everolimus—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	2.12e-05	0.000187	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	2.12e-05	0.00249	CbGpPWpGaD
Everolimus—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	2.11e-05	0.000186	CcSEcCtD
Everolimus—Headache—Ritonavir—acquired immunodeficiency syndrome	2.11e-05	0.000186	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	2.08e-05	0.00245	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.06e-05	0.00243	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.06e-05	0.00243	CbGpPWpGaD
Everolimus—Vomiting—Saquinavir—acquired immunodeficiency syndrome	2.06e-05	0.000181	CcSEcCtD
Everolimus—Dizziness—Lamivudine—acquired immunodeficiency syndrome	2.04e-05	0.00018	CcSEcCtD
Everolimus—Rash—Saquinavir—acquired immunodeficiency syndrome	2.04e-05	0.00018	CcSEcCtD
Everolimus—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	2.04e-05	0.00018	CcSEcCtD
Everolimus—Headache—Saquinavir—acquired immunodeficiency syndrome	2.03e-05	0.000179	CcSEcCtD
Everolimus—FKBP1A—Disease—CCR5—acquired immunodeficiency syndrome	2.02e-05	0.00238	CbGpPWpGaD
Everolimus—Nausea—Ritonavir—acquired immunodeficiency syndrome	2e-05	0.000176	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2e-05	0.00235	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	1.99e-05	0.00234	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	1.98e-05	0.00233	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	1.97e-05	0.00232	CbGpPWpGaD
Everolimus—Vomiting—Lamivudine—acquired immunodeficiency syndrome	1.96e-05	0.000173	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—IL6—acquired immunodeficiency syndrome	1.96e-05	0.00231	CbGpPWpGaD
Everolimus—Rash—Lamivudine—acquired immunodeficiency syndrome	1.95e-05	0.000172	CcSEcCtD
Everolimus—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	1.95e-05	0.000172	CcSEcCtD
Everolimus—Headache—Lamivudine—acquired immunodeficiency syndrome	1.94e-05	0.000171	CcSEcCtD
Everolimus—Nausea—Saquinavir—acquired immunodeficiency syndrome	1.92e-05	0.00017	CcSEcCtD
Everolimus—MTOR—Immune System—CCR2—acquired immunodeficiency syndrome	1.91e-05	0.00225	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	1.84e-05	0.00217	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	1.84e-05	0.00217	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—acquired immunodeficiency syndrome	1.84e-05	0.00217	CbGpPWpGaD
Everolimus—Nausea—Lamivudine—acquired immunodeficiency syndrome	1.83e-05	0.000162	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	1.83e-05	0.00215	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	1.81e-05	0.00213	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	1.8e-05	0.00212	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNA1—acquired immunodeficiency syndrome	1.72e-05	0.00202	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD79A—acquired immunodeficiency syndrome	1.67e-05	0.00196	CbGpPWpGaD
Everolimus—MTOR—Disease—CXCR4—acquired immunodeficiency syndrome	1.66e-05	0.00195	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.63e-05	0.00192	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.57e-05	0.00185	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.54e-05	0.00182	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.41e-05	0.00166	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.36e-05	0.00161	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD40LG—acquired immunodeficiency syndrome	1.36e-05	0.0016	CbGpPWpGaD
Everolimus—MTOR—Immune System—CSF2—acquired immunodeficiency syndrome	1.34e-05	0.00158	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD8A—acquired immunodeficiency syndrome	1.34e-05	0.00158	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	1.34e-05	0.00158	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.33e-05	0.00156	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-B—acquired immunodeficiency syndrome	1.29e-05	0.00152	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.27e-05	0.0015	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CD4—acquired immunodeficiency syndrome	1.27e-05	0.00149	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.26e-05	0.00148	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.23e-05	0.00145	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.16e-05	0.00137	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.16e-05	0.00137	CbGpPWpGaD
Everolimus—MTOR—Disease—CCR5—acquired immunodeficiency syndrome	1.13e-05	0.00134	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.03e-05	0.00121	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.82e-06	0.00104	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	8.76e-06	0.00103	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.69e-06	0.00102	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.16e-06	0.000961	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNG—acquired immunodeficiency syndrome	7.99e-06	0.000941	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.95e-06	0.000936	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD4—acquired immunodeficiency syndrome	7.72e-06	0.000909	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—acquired immunodeficiency syndrome	7.17e-06	0.000844	CbGpPWpGaD
Everolimus—MTOR—Disease—CD4—acquired immunodeficiency syndrome	7.13e-06	0.000839	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—acquired immunodeficiency syndrome	7.1e-06	0.000836	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—acquired immunodeficiency syndrome	6.85e-06	0.000807	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.8e-06	0.000565	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.59e-06	0.000541	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—acquired immunodeficiency syndrome	4.17e-06	0.000492	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—acquired immunodeficiency syndrome	3.85e-06	0.000454	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.7e-06	0.000318	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.8e-06	0.000212	CbGpPWpGaD
